. 2021 Jun 15;10(12):2640. doi: 10.3390/jcm10122640

Table 6.

DJ1, L1CAM, HE4 and CA125 serum levels in correlation with both clinical and pathological features of endometrial cancer.

			Valid n	Median (IQR)	p Value
DJ1 (ng/mL)	Histological type	E G1-2	50	83.4 (41.4–151.5)	0.191
	Histological type	E G3, non-E	14	69 (22.1–94.5)	0.191
	Myometrial invasion	<50%	47	63.9 (35.4–135.5)	0.331
	Myometrial invasion	≥50%	17	91.1 (51.9–151.5)	0.331
	LN involvement	No	60	78 (38.4–145.2)	0.688
	LN involvement	Yes	4	73.2 (36.4–111.3)	0.688
	Distant metastasis	No	62	83.4 (37.1–142.4)	0.714
	Distant metastasis	Yes	2	56.7 (53.1–60.3)	0.714
	Definitive risk	Low ¹	34	57.8 (39.7–147.9)	0.941
	Definitive risk	High ²	30	86.2 (37.1–128)	0.941
L1CAM (pg/mL)	Histological type	E G1-2	50	1889.5 (1523.5–2418)	0.620
	Histological type	E G3, non-E	14	2132.5 (1460–2345.5)	0.620
	Myometrial invasion	<50%	47	1969 (1528–2355)	0.721
	Myometrial invasion	≥50%	17	1680 (1515–2418)	0.721
	LN involvement	No	60	1919 (1519.3–2389.8)	0.945
	LN involvement	Yes	4	2055.5 (1586.5–2381.8)	0.945
	Distant metastasis	No	62	1919 (1523.5–2355)	0.772
	Distant metastasis	Yes	2	2200.5 (1515–2886)	0.772
	Definitive risk	Low ¹	34	1948.5 (1580–2355)	0.687
	Definitive risk	High ²	30	1837.75 (1469–2418)	0.687
HE4 (pmol/mL)	Histological type	E G1-2	38	65 (51.4–98)	0.276
	Histological type	E G3, non-E	11	76.2 (60.2–153.7)	0.276
	Myometrial invasion	<50%	39	63.7 (51.4–79.2)	0.002
	Myometrial invasion	≥50%	10	148.4 (68.6–255)	0.002
	LN involvement	No	45	65.7 (53.1–89.6)	0.033
	LN involvement	Yes	4	148.4 (105.8–189.4)	0.033
	Distant metastasis	No	47	67.1 (53.1–90)	0.021
	Distant metastasis	Yes	2	284.5 (255–314)	0.021
	Definitive risk	Low ¹	28	61.9 (48.3–79.9)	0.020
	Definitive risk	High ²	21	76.2 (61.1–153.7)	0.020
CA125 (kU/L)	Histological type	E G1-2	47	15.8 (12.4–23.8)	0.837
	Histological type	E G3, non-E	13	17.9 (10.8–24.7)	0.837
	Myometrial invasion	<50%	45	14.9 (10.5–20)	0.009
	Myometrial invasion	≥50%	15	23.8 (16.9–119)	0.009
	LN involvement	No	56	15.8 (10.7–23.6)	0.010
	LN involvement	Yes	4	192.4 (88.2–407.4)	0.010
	Distant metastasis	No	58	16 (10.8–23.8)	0.104
	Distant metastasis	Yes	2	116.7 (23.4–210)	0.104
	Definitive risk	Low ¹	32	15.3 (10.2–19.8)	0.135
	Definitive risk	High ²	28	19 (12.2–41.4)	0.135

Abbreviations: n = number of patients, IQR = interquartile range. ¹ Low definitive risk = endometrial carcinoma G1-2 AND myometrial invasion <50% AND LVSI negative (i.e., adjuvant treatment not recommended) ² High definitive risk = criteria for low risk not met (i.e., adjuvant treatment recommended).